ETF Managers Group’s ImmunityBio IBRX Stock Holding History

ETF Managers Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$298K	Buy	163,948 +64,147	+64%	+$199K	0.01%	538
2022 Q4	$506K	Sell	99,801 -18,326	-16%	-$101K	0.02%	364
2022 Q3	$587K	Sell	118,127 -7,601	-6%	-$34.6K	0.02%	349
2022 Q2	$474K	Buy	125,728 +5,063	+4%	+$20.3K	0.01%	511
2022 Q1	$711K	Buy	120,665 +492	+0.4%	+$3.02K	0.01%	385
2021 Q4	$767K	Sell	120,173 -22,652	-16%	-$170K	0.02%	387
2021 Q3	$1.37M	Buy	142,825 +24,670	+21%	+$271K	0.03%	237
2021 Q2	$1.72M	Buy	118,155 +80,521	+214%	+$1.33M	0.03%	237
2021 Q1	$894K	Sell	37,634 -15,185	-29%	-$394K	0.02%	290
2020 Q4	$758K	Sell	52,819 -7,723	-13%	-$74.3K	0.02%	269
2020 Q3	$435K	Buy	60,542 +32,807	+118%	+$327K	0.01%	335
2020 Q2	$300K	Buy	+27,735	New	+$157K	0.01%	413

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SSWM

Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ETF Managers Group's IBRX Position: Q1 2023 in Review

ETF Managers Group increased its ImmunityBio (IBRX) stake by 64% in Q1 2023, buying an estimated $199K and bringing the position to 163,948 shares worth $298K. The position accounts for 0.01% of the portfolio, ranked #538.

ETF Managers Group first reported a position in IBRX in Q2 2020 and has held it in 12 quarters since. The position peaked at $1.72M in Q2 2021. 147 funds tracked by Wall St. Rank hold IBRX as of Q1 2023.

ETF Managers Group held 163,948 shares of ImmunityBio worth $298K as of Q1 2023.
ETF Managers Group bought 64,147 ImmunityBio shares in Q1 2023, an estimated $199K.
ImmunityBio made up 0.01% of ETF Managers Group's portfolio in Q1 2023, its #538 holding.
ETF Managers Group first reported a position in ImmunityBio in Q2 2020 and has held it in 12 quarters since.
ETF Managers Group's ImmunityBio position peaked at $1.72M in Q2 2021.
147 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.